NOS1 and Parkinson disease: It is a benzothiazole derivative containing a piperazine-1-carbothioamide moiety, designed by means of a hybridization approach of compounds directed against molecular targets involved in the progression of PD, i.e., pramipexole and riluzole, kynurenamine-based nNOS inhibitors, and the calmodulin inhibitor DY-9706e [89,90].